Information Provided By: 
Fly News Breaks for June 11, 2019
TXMD
Jun 11, 2019 | 14:51 EDT
Oppenheimer analyst Jay Olson lowered his price target on TherapeuticsMD to $10 from $13, and his FY19 sales estimates to $25.9M from $32.9M, after the company provided revenue guidance below consensus. Olson, however, kept an Outperform rating on the company based on the potential for TherapeuticsMD to "successfully penetrate and expand the market for treatment of menopausal symptoms" with its two products, Imvexxy and Bijuva.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
